Investigations After Adjuvant Therapy

  • Silvia Dellapasqua
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

More than 2 million women in the US alone are living with a history of breast cancer. Most women in whom breast cancer is diagnosed do not die of the disease: of the 180,000 women who receive a diagnosis of invasive breast cancer in the US every year, more than 80% can expect to survive for at least 5 years [1].


Breast Cancer Bone Mineral Density Breast Cancer Patient Recurrent Breast Cancer Prophylactic Contralateral Mastectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Burstein HJ, Winer EP. Primary care for survivors of breast cancer. NEJM. 2000;343(15):1086–94PubMedCrossRefGoogle Scholar
  2. 2.
    Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, Fitzpatrick R, Vessey M. Routine follow up of breast cancer in primary care: Randomised trial. BMJ. Sep 1996;14;313(7058):665–9CrossRefGoogle Scholar
  3. 3.
    Tomiak E, Piccart M. Routine follow-up of patients after primary therapy for early breast cancer: Changing concepts and challenges for the future. Ann Oncol. 1993;4:199–204PubMedGoogle Scholar
  4. 4.
    Loprinzi CL. It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol. 1994;12(5):881–3.PubMedGoogle Scholar
  5. 5.
    Jiwa M, Thompson J, Coleman R, Reed M. Breast cancer follow-up: Could primary care be the right venue? Curr Med Res Opin. 2006;22(4):625–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Mille D, Roy T, Carrère M, Ray I, Ferdjaoui N, Späth H, Chauvin F, Philip T. Economic impact of harmonizing medical practices: Compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol, April 2000;18(8):1718–24.PubMedGoogle Scholar
  7. 7.
    de Bock GH, Bonnema J, van der Hage J, et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: A meta-analysis and systematic review. J Clin Oncol. 2004;22:4010–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Oxford, United Kingdom, Cochrane Library, CD001768, 1, 2005.Google Scholar
  9. 9.
    Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnositic follow up after treatment of primary breast cancer. JAMA. 1994;271:1593–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Palli D, Russo A, Saieva C, Ciatto S, Rosselli Del Turco M, Distante V, Pacini P, for the National Research Council Project on Breast Cancer Follow-up. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. JAMA. 1999;281(17):1586.PubMedCrossRefGoogle Scholar
  11. 11.
    GIVIO Investigators. Impact of follow up testing on survival and health-related quality of life in breast cancer patients. JAMA. 1994;271:1587–92.CrossRefGoogle Scholar
  12. 12.
    Liberati A. The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Ann Oncol. 1995;6(Suppl 2):41–6.PubMedGoogle Scholar
  13. 13.
    Gulliford T, Opomu M, Wilson E, et al. Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study. BMJ. 1997;314:174–7.PubMedCrossRefGoogle Scholar
  14. 14.
    American Society of Clinical Oncology: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer: Adopted on November 7, 1997, by the American Society of Clinical Oncology. J Clin Oncol. 1998;16:793–5.Google Scholar
  15. 15.
    American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–9.Google Scholar
  16. 16.
    Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. J Clin Oncol. 24(31):1–7.CrossRefGoogle Scholar
  17. 17.
    Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 and BRCA2 mutations. JAMA. 2000;283:617–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer. 1998;34:2000–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidemiol. 1992;136:937–48.PubMedGoogle Scholar
  21. 21.
    Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Grunfeld E, Noorani H, McGahan L, et al. Surveillance mammography after treatment of primary breast cancer: A systematic review. Breast. 2002;11:228–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone Imaging in Metastatic Breast Cancer. J Clin Oncol. 2004;22:2942–53.PubMedCrossRefGoogle Scholar
  24. 24.
    Drotman MB, Machnicki SC, Schwartz LH, et al. Breast cancer: Assessing the use of routine pelvic CT in patient evaluation. Am J Roentgenol. 2001;176:1433–6.Google Scholar
  25. 25.
    Hurria A, Leung D, Trainor K, et al. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag. 2003;12:13–5.PubMedGoogle Scholar
  26. 26.
    Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43:325–9.PubMedGoogle Scholar
  27. 27.
    Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129:147–53.PubMedGoogle Scholar
  28. 28.
    Isasi CR, Moadel RM, Blaufox MD. A metaanalysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicenter cohort study (MARIBS). Lancet. 2005;365:1769–78.PubMedCrossRefGoogle Scholar
  31. 31.
    Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem. 2006;52(3):345–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Hietanen P. Response to follow-up of breast cancer. Strahlentherapie. 1985;161:678–80.PubMedGoogle Scholar
  33. 33.
    Muss HB, Tell GS, Case LD, Robertson P, Atwell BM. Perceptions of follow-up care in women with breast cancer. Am J Clin Oncol. 1991;14:55–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests? Classic Papers, suppl to J Clin Oncol. 2003, 21(9):108–11.CrossRefGoogle Scholar
  35. 35.
    Warmuth MA, Bowen G, Prosnitz L, et al. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey. Cancer. 1998;83:1362–8.Google Scholar
  36. 36.
    Johnson CH, van Heerden JA, Donohue JH, Martin JK Jr, Jackson IT, Ilstrup DM. Oncological aspects of immediate breast reconstruction following mastectomy for malignancy. Arch Surg 1989;124:819–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg. 1994;93:1191–204.PubMedCrossRefGoogle Scholar
  38. 38.
    Petrek JA, Lerner R. Lymphedema. Harris JR, Lippman ME, Morrow M, Osborne K, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:1033–40.Google Scholar
  39. 39.
    Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.PubMedCrossRefGoogle Scholar
  40. 40.
    Pezner RD, Patterson MP, Hill LR, et al. Arm lymphedema in patients treated conservatively for breast cancer: Relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Bertelli G, Venturini M, Forno G, Macchiavello F, Dini D. Conservative treatment of postmastectomy lymphedema: a controlled, randomized trial. Ann Oncol. 1991;2:575–8.PubMedGoogle Scholar
  42. 42.
    Rockson SG. Precipitating factors in lymphedema: Myths and realities. Cancer. 1998;83:2814–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209–16.PubMedGoogle Scholar
  44. 44.
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. Lippman ME, ed. National Institutes of Health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI monographs. No. 1. Washington, D.C.: Government Printing Office, 1986:105-9. (NIH publication no. 86–2860.)Google Scholar
  45. 45.
    Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–501.PubMedGoogle Scholar
  46. 46.
    Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.PubMedGoogle Scholar
  47. 47.
    Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G. Second malignancies following CMF-based adjuvant chemotherapy in respectable breast cancer. Ann Oncol. 1994;5:803–8.PubMedGoogle Scholar
  48. 48.
    Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722–30.PubMedGoogle Scholar
  49. 49.
    Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001;30:67–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.PubMedGoogle Scholar
  51. 51.
    Davidson NE. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr. 1994;16:95–99.PubMedGoogle Scholar
  52. 52.
    Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (ACT) in early stage breast cancer. Breast Cancer Res Treat. 2000;64:61(abstr 224).Google Scholar
  53. 53.
    Minton SE, Munster PN. Chemotherapy induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9:466–72.PubMedGoogle Scholar
  54. 54.
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18.PubMedCrossRefGoogle Scholar
  55. 55.
    Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–69.Google Scholar
  57. 57.
    Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17:1488–92.PubMedGoogle Scholar
  58. 58.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.PubMedGoogle Scholar
  59. 59.
    Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat. 1998;48:81–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol. 1992;45:118–28.PubMedCrossRefGoogle Scholar
  61. 61.
    Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91:1654–62.PubMedCrossRefGoogle Scholar
  62. 62.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedCrossRefGoogle Scholar
  63. 63.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.Google Scholar
  64. 64.
    Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341–7.PubMedGoogle Scholar
  65. 65.
    Powles TJ, McCloskey E, Paterson AHG, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736–46.PubMedCrossRefGoogle Scholar
  67. 67.
    Nixon AJ, Manola J, Gelman R, et al. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol. 1998;16:1374–9.PubMedGoogle Scholar
  68. 68.
    Hojris, I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet. 1999;354:1425–30.PubMedCrossRefGoogle Scholar
  69. 69.
    Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol. 1998;16:2625–31 (Erratum, J Clin Oncol. 1999;17:740.PubMedGoogle Scholar
  70. 70.
    Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018–24.PubMedGoogle Scholar
  71. 71.
    Stewart HJ. The Scottish trial of adjuvant tamoxifen in node negative breast cancer. J Natl Cancer Inst Monogr. 1992, 11, 117–20.PubMedGoogle Scholar
  72. 72.
    Nordenskjöld B, Rosell J, Rutqvist LE, et al. The Swedish Breast Cancer Group trail of two versus five years of adjuvant tamoxifen: reduced coronary heart disease death rate in the five years group. Ann Oncol. 2004, 15(Suppl. 3), iii54–iii55 (Abstract 2060).CrossRefGoogle Scholar
  73. 73.
    Grunfeld E, Mant D, Vessey MP, Yudkin P. Evaluating primary care follow-up of breast cancer: Methods and preliminary results of three studies. Ann Oncol. 1995;6(Suppl 2):47–52.PubMedGoogle Scholar
  74. 74.
    Grunfeld E, Fitzpatrick R, Mant D, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: Results from a randomized controlled trial. Br J Gen Pract. 1999 Sep;49(446):705–10.PubMedGoogle Scholar
  75. 75.
    Grunfeld E, Gray A, Mant D, et al. Follow-up of breast cancer in primary care vs specialist care: Results of an economic evaluation. Br J Cancer. 1999;79:1227–33.PubMedCrossRefGoogle Scholar
  76. 76.
    Worster A, Bass MJ, Wood ML. Willingness to follow breast cancer. Survey of family physicians. Can Fam Physician. 1996;42:263–8.PubMedGoogle Scholar
  77. 77.
    Goodwin PJ. Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. Evid Based Med. May 1,2000; 5(3):89.CrossRefGoogle Scholar
  78. 78.
    Rainsbury D. Routine follow up of breast cancer in primary care. BMJ. 1996 313:1547.PubMedCrossRefGoogle Scholar
  79. 79.
    Dixon JM, Norman B. Most recurrences after breast conservation are detected by regular hospital visits. BMJ. 1996;313:1548.PubMedCrossRefGoogle Scholar
  80. 80.
    Grunfeld E, Levine MN, Julian JA, et al. Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician versus Specialist Care. J Clin Oncol. 2006;24(6):848–55.PubMedCrossRefGoogle Scholar
  81. 81.
    Newell S, Sanson-Fisher RW, Girgis A, et al. How well do medical oncologists’ perceptions reflect their patients’ reported physical and psychosocial problems? Data from a survey of five oncologists. Cancer. 1998; 83:1640–51PubMedCrossRefGoogle Scholar
  82. 82.
    Khatcheressian JL, Smith TJ. Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol. 20 February 2006;24(6):835–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Early Breast Cancer Trialists’ Collaborative Group: Effects of Chemotherapy and Hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  84. 84.
    Institute of Medicine and National Research Council, Committee on Cancer Survivorship: Improving care and quality of life, National Cancer Policy Board. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press, 2005.Google Scholar
  85. 85.
    Dewar J. Follow up in breast cancer: A suitable case for reappraisal. BMJ. 1995;310:685.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Medical OncologyEuropean Institute of OncologyMilanItaly

Personalised recommendations